Your browser doesn't support javascript.
loading
Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting.
Kikuchi, Taku; Tsukada, Nobuhiro; Kunisada, Kodai; Matsumoto, Chiaki; Nomura-Yogo, Moe; Oda, Yuki; Sato, Kota; Takei, Tomomi; Ogura, Mizuki; Abe, Yu; Suzuki, Kenshi; Hosoya, Osamu; Ishida, Tadao.
Afiliación
  • Kikuchi T; Department of Hematology, Japanese Red Cross Medical Center, 4-chome-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan. taku_k_1123@mac.com.
  • Tsukada N; Department of Hematology, Japanese Red Cross Medical Center, 4-chome-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan.
  • Kunisada K; Department of Hematology, Japanese Red Cross Medical Center, 4-chome-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan.
  • Matsumoto C; Department of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Nomura-Yogo M; Department of Hematology, Japanese Red Cross Medical Center, 4-chome-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan.
  • Oda Y; Department of Hematology, Japanese Red Cross Medical Center, 4-chome-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan.
  • Sato K; Department of Hematology, Japanese Red Cross Medical Center, 4-chome-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan.
  • Takei T; Department of Hematology, Japanese Red Cross Medical Center, 4-chome-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan.
  • Ogura M; Department of Hematology, Japanese Red Cross Medical Center, 4-chome-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan.
  • Abe Y; Department of Hematology, Japanese Red Cross Medical Center, 4-chome-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan.
  • Suzuki K; Department of Hematology, Japanese Red Cross Medical Center, 4-chome-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan.
  • Hosoya O; Department of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
  • Ishida T; Department of Hematology, Japanese Red Cross Medical Center, 4-chome-1-22 Hiroo, Shibuya-ku, Tokyo, 150-8935, Japan.
Ann Hematol ; 103(9): 3811-3813, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38839622
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Lenalidomida / Anticuerpos Monoclonales / Mieloma Múltiple Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Hematol Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Lenalidomida / Anticuerpos Monoclonales / Mieloma Múltiple Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Hematol Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Alemania